Effects of long-term tamoxifen therapy on the course of chronic autoimmune thyroiditis F. Romero1, D. Ricci2, P. Vitti2, F. Latrofa2 1Hospital Clinicas Universidad Nacional de Asuncion, Paraguay 2 Department of Clinical and Experimental Medicine, Endocrinology Unit, University Hospital of Pisa, Italy To investigate the effects of tamoxifen treatment on the course of chronic autoimmune thyroiditis (Hashimot’s thyroiditis-HT), serum thyroperoxidase autoantibodies (TPOAb) titres and thyroid function were evaluated retrospectively before and after 5 years in patients with chronic autoimmune thyroiditis and breast cancer that had been treated with tamoxifen (group A, 10 women) or not (group B, 10 women). Before tamoxifen treatment, 2 patients of group A and 4 of group B were receiving L-T4 replacement therapy. The remaining patients were euthyroid. Euthyroid patients who developed hypothyroidism and hypothyroid patients who required a higher L-T4 replacement dose at the end of follow-up were considered to have a reduction of thyroid function. Comparing final with starting titres, TPOAb increased in 1 patient of group A and in 5 of group B, whereas resulted unchanged or reduced in 9 patients of group A and in 5 of group B, respectively (p=0.07). Thyroid function was reduced in 4 patients of group A and in 8 patients of group B while remained unchanged in 6 patients of group A and in 2 patients of group B (p=0.05). When the menopause state was evaluated in group A, 6 were in pre- and 4 in post-menopause before tamoxifen treatment. At the end of follow-up, thyroid function was reduced in 5 and unchanged in 1 out of 6 patients in pre-menopause, whereas resulted unchanged in 1 and diminished in 3 out of 4 patients in post-menopause (p=0.07). In conclusion, long-term tamoxifen treatment prevented the increase of serum TPOAb titres and the reduction of thyroid function in patients with HT and breast cancer. This protective role may be related to the presence of estrogen receptors in thyroid cells and appear to be more relevant in post-menopause. Data from a larger group of patients are necessary to confirm these results.
Effects Of Long-term Tamoxifen Therapy On The Course Of Chronic Autoimmune Thyroiditis
D. Ricci;P. Vitti;F. Latrofa
2019-01-01
Abstract
Effects of long-term tamoxifen therapy on the course of chronic autoimmune thyroiditis F. Romero1, D. Ricci2, P. Vitti2, F. Latrofa2 1Hospital Clinicas Universidad Nacional de Asuncion, Paraguay 2 Department of Clinical and Experimental Medicine, Endocrinology Unit, University Hospital of Pisa, Italy To investigate the effects of tamoxifen treatment on the course of chronic autoimmune thyroiditis (Hashimot’s thyroiditis-HT), serum thyroperoxidase autoantibodies (TPOAb) titres and thyroid function were evaluated retrospectively before and after 5 years in patients with chronic autoimmune thyroiditis and breast cancer that had been treated with tamoxifen (group A, 10 women) or not (group B, 10 women). Before tamoxifen treatment, 2 patients of group A and 4 of group B were receiving L-T4 replacement therapy. The remaining patients were euthyroid. Euthyroid patients who developed hypothyroidism and hypothyroid patients who required a higher L-T4 replacement dose at the end of follow-up were considered to have a reduction of thyroid function. Comparing final with starting titres, TPOAb increased in 1 patient of group A and in 5 of group B, whereas resulted unchanged or reduced in 9 patients of group A and in 5 of group B, respectively (p=0.07). Thyroid function was reduced in 4 patients of group A and in 8 patients of group B while remained unchanged in 6 patients of group A and in 2 patients of group B (p=0.05). When the menopause state was evaluated in group A, 6 were in pre- and 4 in post-menopause before tamoxifen treatment. At the end of follow-up, thyroid function was reduced in 5 and unchanged in 1 out of 6 patients in pre-menopause, whereas resulted unchanged in 1 and diminished in 3 out of 4 patients in post-menopause (p=0.07). In conclusion, long-term tamoxifen treatment prevented the increase of serum TPOAb titres and the reduction of thyroid function in patients with HT and breast cancer. This protective role may be related to the presence of estrogen receptors in thyroid cells and appear to be more relevant in post-menopause. Data from a larger group of patients are necessary to confirm these results.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
